{
    "clinical_study": {
        "@rank": "36879", 
        "arm_group": [
            {
                "arm_group_label": "T+O FDC dosage 1", 
                "arm_group_type": "Experimental", 
                "description": "Low dose"
            }, 
            {
                "arm_group_label": "T+O FDC dosage 2", 
                "arm_group_type": "Experimental", 
                "description": "High dose"
            }, 
            {
                "arm_group_label": "ICS/LABA FDC Dosage 1", 
                "arm_group_type": "Active Comparator", 
                "description": "Low dose"
            }, 
            {
                "arm_group_label": "ICS/LABA FDC Dosage 2", 
                "arm_group_type": "Active Comparator", 
                "description": "High dose"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of the trial is to compare the lung function profile of once daily treatment\n      with tiotropium+olodaterol FDC [2.5/ 5\u00b5g and 5/ 5\u00b5g] delivered by the RESPIMAT with the lung\n      function profile of twice daily treatment with fluticasone propionate+salmeterol FDC\n      [250/50\u00b5g and 500/50\u00b5g] delivered by the Accuhaler\u00ae after 6 weeks of treatment."
        }, 
        "brief_title": "Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Disease, Chronic Obstructive", 
        "condition_browse": {
            "mesh_term": [
                "Chronic Disease", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Diagnosis of chronic obstructive pulmonary disease\n\n          2. Relatively stable airway obstruction with a post-bronchodilator 30% </= Forced\n             Expiratory Volume in 1 second (FEV1)<80% of predicted normal and a\n             post-bronchodilator FEV1/(Forced Vital Capacity)FVC <70%\n\n          3. Male or female patients, 40 years of age or older\n\n          4. Smoking history of more than 10 pack years\n\n          5. Ability to perform technically acceptable pulmonary function tests and maintain\n             records\n\n          6. Ability to inhale medication in a competent manner from the RESPIMAT Inhaler,\n             Accuhaler and from a metered dose inhaler (MDI)\n\n        Exclusion criteria:\n\n          1. Significant disease other than COPD\n\n          2. COPD exacerbation that required treatment with antibiotics, systemic steroids (oral\n             or iv) or hospitalization in the last 3 months.\n\n          3. Clinically relevant abnormal lab values\n\n          4. History of asthma\n\n          5. Diagnosis of thyrotoxicosis\n\n          6. Diagnosis of paroxysmal tachycardia\n\n          7. History of myocardial infarction\n\n          8. Unstable or life-threatening cardiac arrhythmia\n\n          9. Hospitalization for heart failure within the past year\n\n         10. Known active tuberculosis\n\n         11. malignancy for which patient has undergone resection, radiation therapy or\n             chemotherapy within last five years\n\n         12. History of life-threatening pulmonary obstruction\n\n         13. History of cystic fibrosis\n\n         14. Clinically evident bronchiectasis\n\n         15. History of significant alcohol or drug abuse\n\n         16. History of thoracotomy with pulmonary resection\n\n         17. oral or patch \u00df-adrenergics\n\n         18. Oral corticosteroid medication within 6 weeks prior to Visit 1\n\n         19. Regular use daytime oxygen therapy for more than one hour per day\n\n         20. Pulmonary rehabilitation program in the six weeks prior to the screening visit\n\n         21. Investigational drug within one month or six half lives (whichever is greater) prior\n             to screening visit\n\n         22. Known hypersensitivity to \u00df-adrenergic drugs, BAC, EDTA\n\n         23. Pregnant or nursing women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "232", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01969721", 
            "org_study_id": "1237.11", 
            "secondary_id": "2013-000808-41"
        }, 
        "intervention": [
            {
                "arm_group_label": "ICS/LABA FDC Dosage 1", 
                "description": "low dose", 
                "intervention_name": "fluticasone propionate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ICS/LABA FDC Dosage 1", 
                "intervention_name": "salmeterol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "T+O FDC dosage 2", 
                "description": "placebo/dummy for blinding purposes", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ICS/LABA FDC Dosage 2", 
                "description": "placebo/dummy for blinding purposes", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "T+O FDC dosage 2", 
                "description": "tiotropium high dose", 
                "intervention_name": "tiotropium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "T+O FDC dosage 1", 
                "intervention_name": "olodaterol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "T+O FDC dosage 2", 
                "intervention_name": "olodaterol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "T+O FDC dosage 1", 
                "description": "placebo/dummy for blinding purposes", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ICS/LABA FDC Dosage 1", 
                "description": "placebo/dummy for blinding purposes", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "T+O FDC dosage 1", 
                "description": "tiotropium low dose", 
                "intervention_name": "tiotropium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ICS/LABA FDC Dosage 2", 
                "description": "low dose", 
                "intervention_name": "fluticasone propionate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ICS/LABA FDC Dosage 2", 
                "intervention_name": "salmeterol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Salmeterol", 
                "Fluticasone", 
                "Tiotropium"
            ]
        }, 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Genk", 
                        "country": "Belgium"
                    }, 
                    "name": "1237.11.32002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium"
                    }, 
                    "name": "1237.11.32001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyjov", 
                        "country": "Czech Republic"
                    }, 
                    "name": "1237.11.42003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rokycany", 
                        "country": "Czech Republic"
                    }, 
                    "name": "1237.11.42004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tabor", 
                        "country": "Czech Republic"
                    }, 
                    "name": "1237.11.42002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Trebic", 
                        "country": "Czech Republic"
                    }, 
                    "name": "1237.11.42001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hvidovre", 
                        "country": "Denmark"
                    }, 
                    "name": "1237.11.45002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kolding", 
                        "country": "Denmark"
                    }, 
                    "name": "1237.11.45004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Odense C", 
                        "country": "Denmark"
                    }, 
                    "name": "1237.11.45001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Silkeborg", 
                        "country": "Denmark"
                    }, 
                    "name": "1237.11.45003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gro\u00dfhansdorf", 
                        "country": "Germany"
                    }, 
                    "name": "1237.11.49003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany"
                    }, 
                    "name": "1237.11.49005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mannheim", 
                        "country": "Germany"
                    }, 
                    "name": "1237.11.49001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00f6nchengladbach", 
                        "country": "Germany"
                    }, 
                    "name": "1237.11.49004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wiesbaden", 
                        "country": "Germany"
                    }, 
                    "name": "1237.11.49002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Debrecen", 
                        "country": "Hungary"
                    }, 
                    "name": "1237.11.36001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pecs", 
                        "country": "Hungary"
                    }, 
                    "name": "1237.11.36004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Szeged", 
                        "country": "Hungary"
                    }, 
                    "name": "1237.11.36003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Szombathely", 
                        "country": "Hungary"
                    }, 
                    "name": "1237.11.36002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Almelo", 
                        "country": "Netherlands"
                    }, 
                    "name": "1237.11.31005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Breda", 
                        "country": "Netherlands"
                    }, 
                    "name": "1237.11.31002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Eindhoven", 
                        "country": "Netherlands"
                    }, 
                    "name": "1237.11.31006 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heerlen", 
                        "country": "Netherlands"
                    }, 
                    "name": "1237.11.31001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hoorn", 
                        "country": "Netherlands"
                    }, 
                    "name": "1237.11.31007 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zutphen", 
                        "country": "Netherlands"
                    }, 
                    "name": "1237.11.31003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Alicante", 
                        "country": "Spain"
                    }, 
                    "name": "1237.11.34003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "1237.11.34001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pozuelo de Alarc\u00f3n", 
                        "country": "Spain"
                    }, 
                    "name": "1237.11.34002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden"
                    }, 
                    "name": "1237.11.46001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Czech Republic", 
                "Denmark", 
                "Germany", 
                "Hungary", 
                "Netherlands", 
                "Spain", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "Randomized, Double-blind, Double-dummy, Active-controlled, 4 Period Complete Cross-over Study to Compare the Effect on Lung Function of 6 Weeks Once Daily Treatment With Orally Inhaled Tiotropium+Olodaterol Fixed Dose Combination Delivered by the Respimat\u00ae Inhaler vs. 6 Weeks Twice Daily Treatment With Fluticasone Propionate+Salmeterol Fixed Dose Combination Delivered by the Accuhaler\u00ae in Patients With Chronic Obstructive Pulmonary Disease (COPD)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Public Service Health, Food Chain Safety, Environment", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: The Danish Health and Medicines Authority", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hungary: National Institute of Pharmacy", 
                "Netherlands: Central Committee Research Involving Human Subjects", 
                "Spain: Spanish Agency of Medicines", 
                "Sweden: Medical Products Agency", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "FEV1 AUC0-12h - change from baseline after 6 weeks of treatment", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01969721"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "FEV1 AUC0-24h - change from baseline 6-weeks of treatment.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6 weeks"
            }, 
            {
                "measure": "Trough FEV1- change from baseline 6-weeks of treatment.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6 weeks"
            }, 
            {
                "measure": "FEV1 AUC 12-24 h - change from baseline 6-weeks of treatment.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6 weeks"
            }, 
            {
                "measure": "Peak 0-3h FEV1- change from baseline 6-weeks of treatment.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6 weeks"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}